# Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis

> **NCT03345940** · PHASE4 · TERMINATED · sponsor: **Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta** · enrollment: 55 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Fingolimod
- **DRUG:** Dimethyl Fumarate

## Key facts

- **NCT ID:** NCT03345940
- **Lead sponsor:** Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-30
- **Primary completion:** 2019-10-30
- **Final completion:** 2019-10-30
- **Target enrollment:** 55 (ACTUAL)
- **Why stopped:** termination of the study due to the slowness of the recruitment activity, according to the contract signed with the Sponsor
- **Last updated:** 2019-10-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03345940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03345940, "Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03345940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*